Last reviewed · How we verify

Monoclonal Antibody J591

BZL Biologics · Phase 2 active Small molecule

Monoclonal Antibody J591 is a Small molecule drug developed by BZL Biologics. It is currently in Phase 2 development.

At a glance

Generic nameMonoclonal Antibody J591
SponsorBZL Biologics
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Monoclonal Antibody J591

What is Monoclonal Antibody J591?

Monoclonal Antibody J591 is a Small molecule drug developed by BZL Biologics.

Who makes Monoclonal Antibody J591?

Monoclonal Antibody J591 is developed by BZL Biologics (see full BZL Biologics pipeline at /company/bzl-biologics).

What development phase is Monoclonal Antibody J591 in?

Monoclonal Antibody J591 is in Phase 2.

Related